Potential risks include: Enhanced gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) Increased risk of nutritional deficiencies and protein malnutrition Potential worsening of gastroesophageal reflux symptoms Dehydration risk and acute kidney injury, particularly during dose escalation Increased risk of gallbladder disease and complications Risk of intestinal obstruction or ileus Diabetic retinopathy progression in patients with diabetes, particularly with rapid glycemic improvement Hypoglycemia risk, particularly in patients on insulin or sulfonylureas Cost considerations and insurance coverage challenges Rare but serious risks including pancreatitis and thyroid C-cell tumors (boxed warning) Clinicians must engage in shared decision-making with patients, carefully weighing these potential benefits against risks in the context of individual patient circumstances, surgical outcomes, comorbidities, and treatment goals

Novo Nordisk Also Produces Wegovy, Another Semaglutide-Based Medication, Which Is Specifically Approved as a Weight Loss Drug
Women often see more accumulating around the midsection or waist as opposed to the thighs and butt
Additional Benefits Beyond its primary uses, semaglutide offers other health benefits
And it delivers 12 GRAMS of prebiotic fiber in just 2 tablespoons